Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study
Close clinical and hormonal monitoring is recommended for patients with high-risk factors before and throughout the course of immunotherapy, particularly during the initial 2 to 4 months of PD-1 inhibitor treatment.
Authors
- Pengfei Zhao (ORCID: https://orcid.org/0000-0002-9590-3469)
- Jia Li (ORCID: https://orcid.org/0000-0002-5153-1288)
- Wenming Ma
- Lihong Yu (ORCID: https://orcid.org/0000-0002-0874-3998)
- Ting Zhao (ORCID: https://orcid.org/0000-0001-5102-0157)
Institutions
- Weifang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1581057
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.59